Prevention of valproic acid-induced neural tube defects by sildenafil citrate

Reproductive Toxicology
Gian Mario Tiboni, Adalisa Ponzano

Abstract

This study was undertaken to test the effects of sildenafil citrate (SC), a type 5 phosphodiesterase inhibitor, on valproic acid (VPA)-induced teratogenesis. On gestation day (GD) 8, ICR (CD-1) mice were treated by gastric intubation with SC at 0 (vehicle), 1.0, 2.5, 5.0 or 10mg/kg. One hour later, animals received a teratogenic dose of VPA (600mg/kg) or vehicle. Developmental endpoints were evaluated near the end of gestation. Twenty-eighth percent of fetuses exposed to VPA had neural tube defects (exencephaly). Pretreatment with SC at 2.5, 5.0 or 10mg/kg significantly reduced the rate of VPA-induced exencephaly to 15.9%, 13.7%, and 10.0%, respectively. Axial skeletal defects were observed in 75.8% of VPA-exposed fetuses. Pre-treatment with SC at 10mg/kg, but not at lower doses, significantly decreased the rate of skeletally affected fetuses to 61.6%. These results show that SC, which prolongs nitric oxide (NO) signaling action protects from VPA-induced teratogenesis.

References

Nov 1, 1984·American Journal of Medical Genetics·J H DiLibertiC J Curry
Jan 1, 1996·Reproduction, Fertility, and Development·D M Boucher, R A Pedersen
Jan 1, 1996·Teratogenesis, Carcinogenesis, and Mutagenesis·E MenegolaE Giavini
Oct 6, 2000·Neuroscience Letters·S Al DeebM Tariq
Nov 13, 2001·Journal of Neurosurgery·E LajeunieD Renier
Jan 11, 2002·Developmental Biology·C P RobertsonH Roelink
Nov 2, 2002·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Alexandra TraisterMiguel Weil
Jan 20, 2004·Brain & Development·Hamza KarabiberNihayet Mehmet
Feb 24, 2004·Molecular Pharmacology·Martin MichaelisJindrich Cinatl
Aug 16, 2005·Acta Neurologica Scandinavica·F J E Vajda, M J Eadie
Nov 23, 2005·Journal of Neurochemistry·Amir NachmanyMiguel Weil
Feb 13, 2007·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Gian Mario TiboniLisa Barbacane
Aug 7, 2007·Birth Defects Research. Part A, Clinical and Molecular Teratology·Peter G AlexanderRocky S Tuan
Jan 30, 2008·Cancer Treatment Reviews·Alfonso Duenas-GonzalezLuis A Herrera
Jan 8, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Peter G WellsAndrea W Wong
Sep 22, 2009·Canadian Journal of Physiology and Pharmacology·Farzad EbrahimiAhmad Reza Dehpour
Jun 15, 2010·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Ozlem OzdegirmenciTayfun Uzbay
Jun 19, 2010·The New England Journal of Medicine·Janneke JentinkUNKNOWN EUROCAT Antiepileptic Study Working Group
Aug 19, 2010·Pharmacological Reviews·Sharron H FrancisDavid Sibley
Jan 20, 2011·BJOG : an International Journal of Obstetrics and Gynaecology·B PellicerA Pellicer
Dec 4, 2012·American Journal of Physiology. Lung Cellular and Molecular Physiology·Elena GammellaLouise Ostergaard
Apr 10, 2013·Acta Cirúrgica Brasileira·Dinani Matoso Fialho de Oliveira ArmstrongDjalma José Fagundes
Feb 8, 2014·Current Pharmaceutical Design·Gian Mario Tiboni, Adalisa Ponzano
May 8, 2014·Reproductive Toxicology·A VerrottiG M Tiboni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.